OTCMKTS:RHHBY - Roche Holdings AG Basel Stock Price, Forecast & News

Roche Holdings AG Basel's stock was trading at $40.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RHHBY stock has decreased by 0.8% and is now trading at $40.57. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche Holdings AG Basel in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Roche Holdings AG Basel.

7 equities research analysts have issued 1 year price targets for Roche Holdings AG Basel's shares. Their forecasts range from $48.00 to $48.00. On average, they expect Roche Holdings AG Basel's share price to reach $48.00 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts' price targets for Roche Holdings AG Basel.

Media headlines about RHHBY stock have trended very negative on Thursday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Roche Holdings AG Basel earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutRoche Holdings AG Basel.

Some companies that are related to Roche Holdings AG Basel include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Roche Holdings AG Basel investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holding Ltd. Genussscheine (ROG), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Intel (INTC), AT&T (T), Cisco Systems (CSCO), Gilead Sciences (GILD) and CVS Health (CVS).

Roche Holdings AG Basel trades on the OTCMKTS under the ticker symbol "RHHBY."

Roche Holdings AG Basel's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.00%).

RHHBY stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH.

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RHHBY stock can currently be purchased for approximately $40.57.

Roche Holdings AG Basel has a market capitalization of $277.84 billion and generates $61.87 billion in revenue each year. The company earns $13.58 billion in net income (profit) each year or $2.54 on an earnings per share basis. Roche Holdings AG Basel employs 97,735 workers across the globe. View additional information about Roche Holdings AG Basel.

The official website for Roche Holdings AG Basel is http://www.roche.com/.

Roche Holdings AG Basel's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]